Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Democratic Capitol Hill Will Create Challenges For Brand Industry

Executive Summary

The sweep of both houses of Congress in the midterm elections will allow the Democrats the opportunity to push their agenda through must-pass legislation such as the reauthorization of the Prescription Drug User Fee Act
Advertisement

Related Content

Rx Importation Legislation Debate Begins Anew, But Battle Lines Are Familiar
BIO lawyers up
Importation from Canada dropping
Senate Health Committee roster
Greater Regulation Of Pharma By Congress Could Be Risky – FDA’s Gottlieb
Follow-On Biologics Bill IP Provisions Are “Unfavorable” – Wyeth Attorney
AB Or Not AB? Barr & Sandoz Ponder The Biogeneric Substitution Question
FDA Opposes Enzi/Kennedy Drug Safety Bill; Action More Likely Through PDUFA
FDA Opposes Enzi/Kennedy Drug Safety Bill; Action More Likely Through PDUFA
FDA Sees Critical Path Opportunity To Address Follow-On Biologics
Advertisement
UsernamePublicRestriction

Register

PS047749

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel